Further comparison among single- or dual-target tumor cells confirmed that the enhanced avidity effects required both target antigens recognized and mediated by Her2/VEGFR2/CD3 (SO) against MDA-MB-468/Her/VEGFR2 (IC50 = 1.06 pM) in comparison to MDA-MB-468/Her2 (IC50 = 15.85 pM) and MDA-MB-468/VEGFR2 (IC50 = 371.54 pM) (Figure S21). The gene discussed is ERBB2; the disease is neoplasm.